KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Profit After Tax (2016 - 2025)

Arbutus Biopharma's Profit After Tax history spans 17 years, with the latest figure at -$3.8 million for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 70.03% to -$3.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$33.5 million, a 52.09% increase, with the full-year FY2025 number at -$33.5 million, up 52.09% from a year prior.
  • Profit After Tax hit -$3.8 million in Q4 2025 for Arbutus Biopharma, up from -$7.7 million in the prior quarter.
  • Over the last five years, Profit After Tax for ABUS hit a ceiling of $2.5 million in Q2 2025 and a floor of -$24.5 million in Q1 2025.
  • Historically, Profit After Tax has averaged -$16.1 million across 5 years, with a median of -$17.7 million in 2022.
  • Biggest five-year swings in Profit After Tax: plummeted 37.62% in 2021 and later soared 112.74% in 2025.
  • Tracing ABUS's Profit After Tax over 5 years: stood at -$21.3 million in 2021, then dropped by 2.87% to -$21.9 million in 2022, then rose by 11.95% to -$19.3 million in 2023, then surged by 35.11% to -$12.5 million in 2024, then soared by 70.03% to -$3.8 million in 2025.
  • Business Quant data shows Profit After Tax for ABUS at -$3.8 million in Q4 2025, -$7.7 million in Q3 2025, and $2.5 million in Q2 2025.